Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection

The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus in vitro. Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Negatu, Dereje A., González del Río, Rubén, Cacho-Izquierdo, Mónica, Barros-Aguirre, David, Lelievre, Joël, Rullas, Joaquín, Casado, Patricia, Ganapathy, Uday S., Zimmerman, Matthew D., Gengenbacher, Martin, Dartois, Véronique, Dick, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933631/
https://www.ncbi.nlm.nih.gov/pubmed/36688684
http://dx.doi.org/10.1128/aac.01459-22
Descripción
Sumario:The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus in vitro. Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection. The results suggest that tebipenem-avibactam presents an attractive oral drug candidate pair for the treatment of M. abscessus pulmonary disease and could inform the design of clinical trials.

Ejemplares similares